Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

[1]  D. Harper,et al.  Factors Affecting the Detection Rate of Human Papillomavirus , 2003, The Annals of Family Medicine.

[2]  K. Jansen,et al.  Human papillomavirus vaccines and prevention of cervical cancer. , 2004, Annual review of medicine.

[3]  D. Lowy,et al.  Papillomavirus-like particle vaccines. , 2000, Journal of the National Cancer Institute. Monographs.

[4]  D. Galloway.  Papillomavirus vaccines in clinical trials. , 2003, The Lancet. Infectious diseases.

[5]  F. Bray,et al.  Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost , 2004, International journal of cancer.

[6]  S. Sanjosé,et al.  Human papillomavirus in cervical cancer , 2002, Current oncology reports.

[7]  W. Quint,et al.  Technical Advance Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human Papillomaviruses , 1998 .

[8]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[9]  C. Woodman,et al.  Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia , 2003, The Lancet.

[10]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[11]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[12]  A. Mandić,et al.  Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. Hollema,et al.  Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas , 1996, Journal of clinical microbiology.

[14]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[15]  Wim Quint,et al.  Development and Clinical Evaluation of a Highly Sensitive PCR-Reverse Hybridization Line Probe Assay for Detection and Identification of Anogenital Human Papillomavirus , 1999, Journal of Clinical Microbiology.

[16]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[17]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.

[18]  S. Franceschi,et al.  Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.

[19]  E. Franco,et al.  Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  A. Moscicki,et al.  Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. , 2004, The Journal of infectious diseases.

[21]  J. T. Ulrich,et al.  Monophosphoryl Lipid A as an Adjuvant , 1995 .

[22]  L. van Doorn,et al.  Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping , 2001, The Journal of pathology.

[23]  C. Wheeler,et al.  Short‐Term Fluctuations in the Detection of Cervical Human Papillomavirus DNA , 1996, Obstetrics and gynecology.

[24]  P. Berger,et al.  Christianity and Democracy: The Global Picture , 2004 .

[25]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[26]  D. Lowy,et al.  Chapter 16: Prophylactic human papillomavirus vaccines. , 2003, Journal of the National Cancer Institute. Monographs.

[27]  F. Vogel.  Improving vaccine performance with adjuvants. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Lowy,et al.  Prophylactic human papillomavirus vaccines. , 2006, The Journal of clinical investigation.

[29]  F. Aoki,et al.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes. , 2002, The New England journal of medicine.

[30]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[31]  M. Weinstein,et al.  A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine , 2003, International journal of cancer.

[32]  C. Peyton,et al.  Genotyping of Human Papillomavirus in Liquid Cytology Cervical Specimens by the PGMY Line Blot Assay and the SPF10 Line Probe Assay , 2002, Journal of Clinical Microbiology.

[33]  Modeling the time dependence of the association between human papillomavirus infection and cervical cancer precursor lesions. , 2003, American journal of epidemiology.

[34]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[35]  Michal Abrahamowicz,et al.  The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[37]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[38]  D. Harper,et al.  Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences. , 2002, American journal of obstetrics and gynecology.

[39]  M. Schiffman,et al.  Human Papillomavirus Epidemiology and Public Health , 2022 .